Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial

Authors

  • Yenny Dian Andayani Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin General Hospital, Palembang, Indonesia
  • Mgs. Irsan Saleh Department of Pharmacology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Aru Wisaksono Sudoyo Division of Haematology and Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Zulkhair Ali Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin General Hospital, Palembang, Indonesia
  • Legiran Legiran Department of Anatomy, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
  • Radiyati Umi Partan Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin Hospital, Palembang, Indonesia
  • Eddy Yuristo Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin General Hospital, Palembang, Indonesia
  • Fadhyl Zuhry Lubis Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin General Hospital, Palembang, Indonesia

Keywords:

Hand Foot Syndrome, C-Reactive Protein, Extra Virgin Olive Oil, Capecitabine

Abstract

Background: Hand Foot Syndrome (HFS) is a frequent adverse effect observed in patients undergoing capecitabine chemotherapy, often leading to treatment disruptions and dose adjustments. Elevated C-Reactive Protein (hs-CRP) levels have been associated with the development of HFS. This study aimed to assess the potential of unrefined Extra Virgin Olive Oil (EVOO) supplementation in mitigating HFS and hs-CRP elevation among individuals receiving capecitabine chemotherapy. Methods: Between November 2022 and May 2023, forty-five eligible participants were enrolled in this randomized trial. Patients with advanced colorectal or breast cancer were randomly allocated into three groups: an intervention group receiving unrefined EVOO supplementation (30 mL per day) alongside capecitabine, a placebo group receiving refined extra light olive oil (ELOO) supplementation (30 mL per day) alongside capecitabine, and a control group receiving capecitabine alone. The masking of both placebo and intervention groups was ensured through identical packaging and instructions, maintaining participant and physician blindness to the assigned treatments. Randomization, achieved via computer-generated sequences, ensured even distribution among the three groups. Results: HFS incidences were notably lower in the EVOO group (13.3%) compared to the placebo (66.7%) and control (80%) groups. Instances of Grade 2 or more severe HFS were observed in 20% of placebo and 40% of control group patients. No cases of severe HFS were reported in the EVOO group. Moreover, EVOO supplementation led to a significant reduction in hs-CRP levels when contrasted with the placebo and control groups. These findings suggest that EVOO may serve as a preventive measure against HFS and exhibit anti-inflammatory effects in patients undergoing capecitabine chemotherapy. Conclusion: This study demonstrates the potential benefits of incorporating unrefined EVOO into the regimen of patients undergoing capecitabine chemotherapy. EVOO supplementation was associated with lower incidences of HFS and a reduction in hs-CRP levels, indicating its possible role in preventing HFS development and mitigating inflammation.

References

Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020;14(1):442. doi:10.4081/oncol.2020.442

Urakawa R, Tarutani M, Kubota K, Uejima E. Hand Foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy. J Cancer. 2019;10(20):4846-51. doi:10.7150/jca.31059

Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016;15(12):1625-33. doi:10.1080/14740338.2016.1238067

Watts K, Wills C, Madi A, et al. Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. Int J Cancer. 2022;151(6):957-66. doi:10.1002/ijc.34046

Kanbayashi Y, Taguchi T, Ishikawa T, Otsuji E, Takayama K. Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study. Oncology. Published online April 19, 2023:1. doi:10.1159/000529851

Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787-94. doi:10.1016/j.jaad.2014.03.019

Jimenez-Lopez C, Carpena M, Lourenço-Lopes C, et al. Bioactive compounds and quality of extra virgin olive oil. Foods. 2020;9(8):1014. doi:10.3390/foods9081014

Pozzetti L, Ferrara F, Marotta L, et al. Extra virgin olive oil extracts of indigenous southern tuscany cultivar act as anti-inflammatory and vasorelaxant nutraceuticals. Antioxidants. 2022;11(3):437. doi:10.3390/antiox11030437

Saif MW, Elfiky AA. Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. J Support Oncol. 2007;5(7):337-343.

de Queiroz MVR, de Medeiros ACTR, Toledo SP, de Abreu Sarmenghi KD, de Vasconcellos VF. Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation. ecancermedicalscience. 2022;16:1390. doi:10.3332/ecancer.2022.1390

Segura-Carretero A, Curiel JA. Current disease-targets for oleocanthal as promising natural therapeutic agent. Int J Mol Sci. 2018;19(10):2899. doi:10.3390/ijms19102899

Murphy R. Extra-virgin olive oil has similar activity to ibuprofen. Nat Clin Pract Rheumatol. 2005;1(2):66-66. doi:10.1038/ncprheum0023

Liang J, Bonvino NP, Hung A, Karagiannis TC. In silico characterisation of olive phenolic compounds as potential cyclooxygenase modulators. Part 1. J Mol Graph Model. 2020;101:107719. doi:10.1016/j.jmgm.2020.107719

Siddique AB, Kilgore PCSR, Tajmim A, et al. Oleocanthal as a dual c-MET-COX2 inhibitor for the control of lung cancer. Nutrients. 2020;12(6). doi:10.3390/nu12061749

Costa V, Costa M, Videira RA, Andrade PB, Paiva-Martins F. Anti-inflammatory activity of olive oil polyphenols—The role of oleacein and its metabolites. Biomedicines. 2022;10(11):2990. doi:10.3390/biomedicines10112990

Downloads

Published

2024-01-12

How to Cite

Andayani, Y. D., Saleh, M. I., Sudoyo, A. W., Ali, Z., Legiran, L., Partan, R. U., Yuristo, E., & Lubis, F. Z. (2024). Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial. Acta Medica Indonesiana, 55(4), 396. Retrieved from https://actamedindones.org/index.php/ijim/article/view/2534

Issue

Vol. 55 No. 4 (2023): Acta Medica Indonesiana

Section

ORIGINAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.